Morgan Stanley
CRDF icon

Morgan Stanley’s Cardiff Oncology CRDF Stock Holding History

Morgan Stanley’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$91.2K Sell
56,306
-179,528
-76% -$369K ﹤0.01% 6205
2025
Q4 		$663K Sell
235,834
-74,825
-24% -$174K ﹤0.01% 5373
2025
Q3 		$640K Sell
310,659
-485,087
-61% -$1.34M ﹤0.01% 5403
2025
Q2 		$2.51M Buy
795,746
+97,218
+14% +$297K ﹤0.01% 4563
2025
Q1 		$2.19M Buy
698,528
+156,139
+29% +$617K ﹤0.01% 4544
2024
Q4 		$2.35M Buy
542,389
+44,247
+9% +$138K ﹤0.01% 4593
2024
Q3 		$1.33M Sell
498,142
-15,082
-3% -$35.6K ﹤0.01% 4880
2024
Q2 		$1.14M Buy
513,224
+433,799
+546% +$1.63M ﹤0.01% 4881
2024
Q1 		$424K Buy
79,425
+48,945
+161% +$130K ﹤0.01% 5388
2023
Q4 		$45.1K Buy
30,480
+11,480
+60% +$13.9K ﹤0.01% 6418
2023
Q3 		$26.4K Buy
19,000
+3,287
+21% +$5.54K ﹤0.01% 6402
2023
Q2 		$23.1K Sell
15,713
-188,135
-92% -$303K ﹤0.01% 6526
2023
Q1 		$336K Sell
203,848
-76,918
-27% -$132K ﹤0.01% 5467
2022
Q4 		$393K Sell
280,766
-95,970
-25% -$137K ﹤0.01% 5360
2022
Q3 		$580K Buy
376,736
+13,017
+4% +$31.3K ﹤0.01% 5194
2022
Q2 		$800K Buy
363,719
+152,265
+72% +$255K ﹤0.01% 5158
2022
Q1 		$524K Sell
211,454
-339,520
-62% -$1.2M ﹤0.01% 5380
2021
Q4 		$3.31M Buy
550,974
+442,874
+410% +$2.64M ﹤0.01% 4159
2021
Q3 		$719K Sell
108,100
-359,361
-77% -$2.26M ﹤0.01% 5281
2021
Q2 		$3.11M Buy
467,461
+442,072
+1,741% +$3.75M ﹤0.01% 4253
2021
Q1 		$235K Buy
25,389
+8,018
+46% +$97.4K ﹤0.01% 5564
2020
Q4 		$313K Buy
17,371
+5,751
+49% +$101K ﹤0.01% 5348
2020
Q3 		$165K Sell
11,620
-12,719
-52% -$84K ﹤0.01% 5206
2020
Q2 		$122K Buy
24,339
+11,023
+83% +$22.6K ﹤0.01% 5307
2020
Q1 		$13K Sell
13,316
-1,572
-11% -$2.22K ﹤0.01% 5949
2019
Q4 		$18K Sell
14,888
-10,134
-41% -$14.4K ﹤0.01% 6119
2019
Q3 		$38K Sell
25,022
-2,057
-8% -$4K ﹤0.01% 5821
2019
Q2 		$68K Buy
27,079
+26,976
+26,190% +$86.5K ﹤0.01% 5488
2019
Q1 		$0 Buy
103
+6
+6% +$21 ﹤0.01% 6606
2018
Q4 		$0 Buy
97
+34
+54% +$155 ﹤0.01% 6609
2018
Q3 		$0 Buy
63
+7
+13% +$33 ﹤0.01% 6721
2018
Q2 		$0 Sell
56
-3
-5% -$50 ﹤0.01% 6674
2018
Q1 		$1K Sell
59
-25
-30% -$616 ﹤0.01% 6530
2017
Q4 		$2K Sell
84
-61
-42% -$2.7K ﹤0.01% 6439
2017
Q3 		$8K Sell
145
-884
-86% -$55.1K ﹤0.01% 6209
2017
Q2 		$93K Sell
1,029
-32
-3% -$2.06K ﹤0.01% 5663
2017
Q1 		$89K Sell
1,061
-1,242
-54% -$169K ﹤0.01% 5641
2016
Q4 		$347K Buy
2,303
+1,049
+84% +$245K ﹤0.01% 5114
2016
Q3 		$405K Sell
1,254
-4,808
-79% -$1.75M ﹤0.01% 4639
2016
Q2 		$1.98M Buy
6,062
+4,569
+306% +$1.57M ﹤0.01% 3430
2016
Q1 		$500K Sell
1,493
-345
-19% -$117K ﹤0.01% 4444
2015
Q4 		$714K Buy
1,838
+250
+16% +$97.9K ﹤0.01% 4292
2015
Q3 		$650K Sell
1,588
-118
-7% -$61.7K ﹤0.01% 4440
2015
Q2 		$1.25M Buy
1,706
+1,145
+204% +$812K ﹤0.01% 4033
2015
Q1 		$275K Buy
561
+394
+236% +$168K ﹤0.01% 5031
2014
Q4 		$52K Sell
167
-635
-79% -$206K ﹤0.01% 5805
2014
Q3 		$264K Sell
802
-4,091
-84% -$1.22M ﹤0.01% 4987
2014
Q2 		$1.23M Buy
4,893
+1,201
+33% +$385K ﹤0.01% 3886
2014
Q1 		$1.52M Sell
3,692
-233
-6% -$101K ﹤0.01% 3661
2013
Q4 		$1.62M Sell
3,925
-101
-3% -$45K ﹤0.01% 3538
2013
Q3 		$2.08M Buy
+4,026
New +$2.29M ﹤0.01% 3179

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

Morgan Stanley's CRDF Position: Q1 2026 in Review

Morgan Stanley reduced its Cardiff Oncology (CRDF) stake by 76% in Q1 2026, selling an estimated $369K and leaving 56,306 shares worth $91.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6205.

Morgan Stanley first reported a position in CRDF in Q3 2013 and has held it in 51 quarters since. The position peaked at $3.31M in Q4 2021. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • Morgan Stanley held 56,306 shares of Cardiff Oncology worth $91.2K as of Q1 2026.
  • Morgan Stanley sold 179,528 Cardiff Oncology shares in Q1 2026, an estimated $369K.
  • Cardiff Oncology made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6205 holding.
  • Morgan Stanley first reported a position in Cardiff Oncology in Q3 2013 and has held it in 51 quarters since.
  • Morgan Stanley's Cardiff Oncology position peaked at $3.31M in Q4 2021.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.